FY2024 EPS Estimates for MediWound Lowered by HC Wainwright

MediWound Ltd. (NASDAQ:MDWD - Free Report) - Research analysts at HC Wainwright dropped their FY2024 EPS estimates for shares of MediWound in a report issued on Wednesday, November 27th. HC Wainwright analyst S. Ramakanth now expects that the biopharmaceutical company will post earnings per share of ($2.61) for the year, down from their prior estimate of ($2.14). HC Wainwright currently has a "Buy" rating and a $25.00 target price on the stock. The consensus estimate for MediWound's current full-year earnings is ($2.47) per share. HC Wainwright also issued estimates for MediWound's Q4 2024 earnings at ($0.54) EPS, Q1 2025 earnings at ($0.56) EPS, Q2 2025 earnings at ($0.64) EPS, Q3 2025 earnings at ($0.71) EPS, Q4 2025 earnings at ($0.77) EPS, FY2025 earnings at ($2.69) EPS, FY2026 earnings at ($1.87) EPS, FY2027 earnings at ($0.80) EPS and FY2028 earnings at $1.06 EPS.

Separately, StockNews.com raised MediWound to a "sell" rating in a research note on Monday, August 5th.

MediWound Stock Performance

MDWD stock traded up $0.62 during midday trading on Monday, hitting $18.10. 74,699 shares of the stock were exchanged, compared to its average volume of 88,916. The stock's 50-day moving average price is $17.17 and its 200-day moving average price is $17.38. The stock has a market cap of $195.25 million, a price-to-earnings ratio of -6.24 and a beta of 0.83. MediWound has a fifty-two week low of $8.81 and a fifty-two week high of $24.00.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. MetLife Investment Management LLC purchased a new stake in MediWound in the 3rd quarter worth approximately $89,000. Rhumbline Advisers acquired a new position in MediWound in the second quarter valued at $131,000. Barclays PLC lifted its position in MediWound by 311.3% during the third quarter. Barclays PLC now owns 11,163 shares of the biopharmaceutical company's stock worth $202,000 after buying an additional 8,449 shares during the period. Point72 Asset Management L.P. acquired a new stake in MediWound in the 3rd quarter worth about $212,000. Finally, Bank of New York Mellon Corp purchased a new stake in MediWound in the 2nd quarter valued at about $342,000. 46.83% of the stock is currently owned by institutional investors and hedge funds.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.